Article thumbnail

Update on optimal use of omalizumab in management of asthma

By Girolamo Pelaia, Luca Gallelli, Teresa Renda, Pasquale Romeo, Maria Teresa Busceti, Rosa Daniela Grembiale, Rosario Maselli, Serafino Antonio Marsico and Alessandro Vatrella


Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2010). A new look at the pathogenesis of asthma. Clin Sci.
  2. A systematic review of economic evaluations of therapy in asthma.
  3. Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention. Pharmacol Ther.
  4. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
  5. (2008). An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy.
  6. (2007). Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma
  7. (2007). Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol.
  8. Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma.
  9. (2005). Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on antiinflammatory activity and clinical efficacy. Clin Exp Allergy.
  10. (2011). Assessment Report (Xolair). Available at: http:// Accessed
  11. (2007). Asthma treatment: ‘Magic bullets which seek their own targets’. Allergy.
  12. (2002). Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA
  13. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL (GOAL) study.
  14. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment.
  15. Chronic inflammation in asthma. Mutat Res.
  16. Churg-Strauss syndrome associated with omalizumab.
  17. Churg-Strauss vasculitis in a patient treated with omalizumab.
  18. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
  19. (2004). Design of baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol.
  20. (1999). Down-regulation of human basophil IgE and FcεRIα surface densities and mediator release by anti-IgE infusions is reversible in vitro and in
  21. Drug therapy: asthma.
  22. Early communication about an ongoing safety review of omalizumab (marketed as Xolair).
  23. (2006). Effect of omalizumab on adenosine 5′-monophosphate responsiveness in subjects with allergic asthma. Int Arch Allergy Immunol.
  24. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.
  25. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
  26. (2008). Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med.
  27. (2005). Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann Allergy Asthma Immunol.
  28. Effects of omalizumab on markers of inflammation in patients with allergic asthma.
  29. Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
  30. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review.
  31. (2004). Efficacy and tolerability of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy.
  32. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis:
  33. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
  34. (2008). Endotyping asthma: new insights into key pathogenetic mechanisms in a complex, heterogeneous disease. Lancet.
  35. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
  36. (2011). Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Available at: Accessed
  37. High prevalence of skin test positivity in severe or difficult-to-treat asthma.
  38. Humanization of an antibody directed against IgE.
  39. (2008). IgE in allergy and asthma today. Nat Rev Immunol.
  40. (2003). Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol.
  41. Incorporating anti-IgE (omalizumab) therapy in clinical practice: practice management implications.
  42. Influence of comorbid conditions on asthma.
  43. Is the prevalence of asthma declining? Systematic review of epidemiological studies.
  44. Italian real-life experience of omalizumab.
  45. Network For Understanding Mechanisms Of Severe Asthma) Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma.
  46. New perspectives in asthma treatment.
  47. (2004). Omalizumab efficacy in allergic disease. Panminerva Med.
  48. Omalizumab for asthma.
  49. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med.
  50. Omalizumab in severe allegic asthma inadequately controlled with standard therapy: a randomized trial.
  51. (2008). Omalizumab in the treatment of severe asthma: efficacy and current problems. Ther Adv Respir Res.
  52. (2003). Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol.
  53. (2010). Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med.
  54. Omalizumab, anti-IgE recombinant humanized monoclonal antibody for the treatment of severe allergic asthma.
  55. Omalizumab: overview of pharmacology and efficacy in asthma.
  56. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma.
  57. (2003). Pharmacodynamics of omalizumab: implications for optimised dosing strategy and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin.
  58. (2007). Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med.
  59. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.
  60. (2009). Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med.
  61. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
  62. (2009). Safety and tolerability of omalizumab. Clin Exp Allergy.
  63. (2007). Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infections. Clin Exp Allergy.
  64. (2011). Safety of omalizumab in asthma. Expert Opin Drug Saf.
  65. (2008). Severe asthma and the omalizumab option. Clin Mol Allergy.
  66. Severe exacerbations predict excess lung function decline in asthma.
  67. Sorkness CA. Anti-immunoglobulin E therapy with omalizumab for asthma.
  68. Targeting airway inflammation in asthma: current and future therapies.
  69. Task Force report on omalizumab-associated anaphylaxis.
  70. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
  71. The antiinflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
  72. (1994). The binding site of a human immunoglobulin E for its high affinity receptor. J Biol Chem.
  73. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective.
  74. The development of allergic inflammation.
  75. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin.
  76. (1997). The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med.
  77. The global burden of asthma: executive summary of the GINA dissemination committee report.
  78. (2008). The use of omalizumab in asthma. Prim Care Respir J.
  79. Tissue distribution and complex generation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys.
  80. (2010). Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update. Eur Ann Allergy Clin Immunol.
  81. (2008). Treatment strategies for allergy and asthma. Nat Rev Immunol.